



## Clinical trial results:

### Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclophosphamide (TEC) in Patients with primary HER-2 neu Negative Mammary Carcinoma

#### Summary

EudraCT number	2008-003064-19
Trial protocol	DE
Global end of trial date	07 July 2016

#### Results information

Result version number	v1 (current)
This version publication date	02 August 2020
First version publication date	02 August 2020
Summary attachment (see zip file)	Study report (NeoTEC_Ergebnisbericht_Behörde_final_2.0_2020-03-

#### Trial information

##### Trial identification

Sponsor protocol code	NeoTEC
-----------------------	--------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	DRKS: DRKS00000162

Notes:

##### Sponsors

Sponsor organisation name	University of Leipzig
Sponsor organisation address	Ritterstr. 26, Leipzig, Germany, 04109
Public contact	Coordinating Investigator, Coordinating Investigator, St. Elisabeth-Krankenhaus Leipzig, Brustzentrum, Leipzig, 0049 341 39 59 493, Dagmar.Langanke@ek-leipzig.de
Scientific contact	Coordinating Investigator, St. Elisabeth-Krankenhaus Leipzig, Brustzentrum, Leipzig, 0049 341 39 59 493, Dagmar.Langanke@ek-leipzig.de

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 December 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	07 July 2016
Global end of trial reached?	Yes
Global end of trial date	07 July 2016
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Estimation of the complete remission rate of invasive tumor cells in the breast confirmed by histological examinations, at surgery.

The treatment of the mammary carcinoma consists in this study normally on 6 chemotherapy cycles of the combination Docetaxel, Epirubicine and Cyclophosphamide (TEC-therapy). Followed by the surgery of the carcinoma, which takes place on day 28 after the last chemotherapy application, at the latest. An evaluation of the response of the treatment is performed after 2 and 4 cycles by use of palpation and mamma sonography. In case of complete remission, partial remission and no change the patient receives further two TEC cycles. In case of progress under therapy the surgery is immediately performed.

Protection of trial subjects:

During the course of the trial, every patient was monitored closely concerning the described safety parameters. Besides the documentation of adverse events, this encompasses the following parameters:

- physical examinations
- Performance status (ECOG, Karnofsky Index)
- Laboratory parameters

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 March 2009
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	5 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 152
Worldwide total number of subjects	152
EEA total number of subjects	152

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	124
From 65 to 84 years	28
85 years and over	0

---

## Subject disposition

### Recruitment

Recruitment details:

Between March 2009 and February 2011, 152 patients were recruited to the NeoTEC study in 15 Trial sites in Germany. The trial contained one arm only.

### Pre-assignment

Screening details:

Eligibility for the study if:

- Women with histologically verified mamma carcinoma (assessment of estrogen and progesterone receptors, grading, negative HER-2/neu status)
- All receptor-negative mamma carcinoma starting from cT1c, all receptor-positive mamma carcinoma starting from cT3, cT4 includes inflammatory mamma carcinoma

### Period 1

Period 1 title	treatment period
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Study arm
-----------	-----------

Arm description:

Chemotherapy combination of Docetaxel, Epirubicine and Cyclophosphamide with breast preserving surgery

Arm type	Experimental
Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Docetaxel 75 mg/m<sup>2</sup> every 3 weeks for 6 cycles

Investigational medicinal product name	Epirubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Epirubicin 75 mg/m<sup>2</sup> every 3 weeks for 6 cycles

Investigational medicinal product name	Cyclophosphamid
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

500 mg/m<sup>2</sup> every 3 weeks for 6 cycles

<b>Number of subjects in period 1</b>	Study arm
Started	152
Completed	148
Not completed	4
Adverse event, serious fatal	2
Consent withdrawn by subject	1
Adverse event, non-fatal	1

---

## Period 2

Period 2 title	Follow-up
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

<b>Arm title</b>	Follow-up
Arm description: 5 years Follow-up after study treatment	
Arm type	Follow-up
No investigational medicinal product assigned in this arm	

<b>Number of subjects in period 2</b>	Follow-up
Started	148
Completed	126
Not completed	22
change to another treating institution	4
removal to another city/contry	2
Lost to follow-up	15
termination due to psychosocial problems	1

## Baseline characteristics

### Reporting groups

Reporting group title	treatment period
-----------------------	------------------

Reporting group description: -

Reporting group values	treatment period	Total	
Number of subjects	152	152	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
arithmetic mean	52.7		
standard deviation	± 11.2	-	
Gender categorical			
Units: Subjects			
Female	152	152	
Male	0	0	
ECOG			
Units: Subjects			
full activity	125	125	
restricted activity	23	23	
self-supply possible	3	3	
no data	1	1	
concomitant disease/s			
Units: Subjects			
yes	79	79	
no	73	73	
type of tumor			
Units: Subjects			
invasive-ductal	134	134	
invasice-lobular	12	12	
other	5	5	
no data	1	1	
receptor status			
Units: Subjects			
ER and PR-positive	55	55	
one of both positive	96	96	

no data	1	1	
TNM stage (sono) Units: Subjects			
T1N0M0	4	4	
T1N1M0	9	9	
T2N0M0	28	28	
T2N1M0	68	68	
T2N2M0	2	2	
T2N3M0	2	2	
T3N0M0	5	5	
T3N1M0	9	9	
T4N0M0	11	11	
T4N1M0	12	12	
T4N2M0	1	1	
no data	1	1	
menopause Units: Subjects			
yes	85	85	
no	66	66	
not available	1	1	
Body Surface Area Units: m <sup>2</sup>			
arithmetic mean	1.81		
standard deviation	± 0.19	-	
BMI Units: kg/m <sup>2</sup>			
arithmetic mean	28.3		
standard deviation	± 6.0	-	
tumor size (sono) Units: mm <sup>2</sup>			
arithmetic mean	1459		
standard deviation	± 6837	-	

### Subject analysis sets

Subject analysis set title	FAS
Subject analysis set type	Full analysis

Subject analysis set description:

Since this study was one-armed, the overall description of all patients is the only useful information

<b>Reporting group values</b>	FAS		
Number of subjects	152		
Age categorical Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			

Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years arithmetic mean standard deviation	52.7 ± 11.2		
Gender categorical Units: Subjects			
Female Male	152 0		
ECOG Units: Subjects			
full activity restricted activity self-supply possible no data	125 23 3 1		
concomitant disease/s Units: Subjects			
yes no	79 73		
type of tumor Units: Subjects			
invasive-ductal invasice-lobular other no data	134 12 5 1		
receptor status Units: Subjects			
ER and PR-positive one of both positive no data	55 96 1		
TNM stage (sono) Units: Subjects			
T1N0M0 T1N1M0 T2N0M0 T2N1M0 T2N2M0 T2N3M0 T3N0M0 T3N1M0 T4N0M0 T4N1M0 T4N2M0 no data	4 9 28 68 2 2 5 9 11 12 1 1		
menopause Units: Subjects			
yes no not available	85 66 1		

Body Surface Area Units: m <sup>2</sup> arithmetic mean standard deviation	1.81 ± 0.19		
BMI Units: kg/m <sup>2</sup> arithmetic mean standard deviation	28.3 ± 6.0		
tumor size (sono) Units: mm <sup>2</sup> arithmetic mean standard deviation	1459 ± 6837		

## End points

### End points reporting groups

Reporting group title	Study arm
-----------------------	-----------

Reporting group description:

Chemotherapy combination of Docetaxel, Epirubicine and Cyclophosphamide with breast preserving surgery

Reporting group title	Follow-up
-----------------------	-----------

Reporting group description:

5 years Follow-up after study treatment

Subject analysis set title	FAS
----------------------------	-----

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Since this study was one-armed, the overall description of all patients is the only useful information

### Primary: pCR b inv

End point title	pCR b inv <sup>[1]</sup>
-----------------	--------------------------

End point description:

no microscopic findings of vital invasive tumor cells in resected tissues post surgery; in breast only, lymph nodes not considered

End point type	Primary
----------------	---------

End point timeframe:

assessed after all cycles of TEC regimen applied and the following surgery

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the single-armed design no statistical analysis but the interval estimate of the end points (primary and secondary) are provided.

End point values	FAS			
Subject group type	Subject analysis set			
Number of subjects analysed	152			
Units: subjects				
complete remission	49			
incomplete remission	103			

<b>Attachments (see zip file)</b>	DRKS-Meldg_NeoTEC-1armig.pdf
-----------------------------------	------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: pCR inv

End point title	pCR inv
-----------------	---------

End point description:

neither in breast nor in axillary lymphnodes invasive rests of tumor; results of pathology; patients with premature EoT did not reach CR

End point type	Secondary
----------------	-----------

End point timeframe:

after all cycles of TEC and surgery (if applicable) = end of treatment

<b>End point values</b>	FAS			
Subject group type	Subject analysis set			
Number of subjects analysed	152			
Units: subjects				
premature EoT	4			
no rests	40			
rests	108			

### Statistical analyses

No statistical analyses for this end point

### Secondary: pCR

End point title	pCR
End point description:	neither invasive nor noninvasive rests of tumor (results of pathology)
End point type	Secondary
End point timeframe:	after EoT

<b>End point values</b>	FAS			
Subject group type	Subject analysis set			
Number of subjects analysed	152			
Units: subjects				
premature EoT	4			
no rests	34			
rests	114			

### Statistical analyses

No statistical analyses for this end point

### Secondary: cCR

End point title	cCR
End point description:	clinical response
End point type	Secondary

End point timeframe:  
after EoT

<b>End point values</b>	FAS			
Subject group type	Subject analysis set			
Number of subjects analysed	150 <sup>[2]</sup>			
Units: subjects				
complete remission	25			
partial remission	99			
minimal response	9			
no change	7			
progressive disease	5			
premature EoT	5			

Notes:

[2] - no data in 2 patients

### Statistical analyses

No statistical analyses for this end point

### Secondary: Regression grade (Sinn 1994)

End point title	Regression grade (Sinn 1994)
End point description:	acc. to Sinn HP et al. Geburtshilfe und Frauenheilkunde 1994:54; 552-558.
End point type	Secondary
End point timeframe:	after EoT

<b>End point values</b>	FAS			
Subject group type	Subject analysis set			
Number of subjects analysed	148			
Units: subjects				
grade 3/4	43			
grade<3	105			

### Statistical analyses

No statistical analyses for this end point

### Secondary: EFS

End point title	EFS
-----------------	-----

End point description:

End point type Secondary

End point timeframe:  
until the end of Study (60 months of FUP)

End point values	FAS			
Subject group type	Subject analysis set			
Number of subjects analysed	152			
Units: subjects				
no event	110			
relapse/ metastasis/ death	42			

### Statistical analyses

No statistical analyses for this end point

### Secondary: OS

End point title OS

End point description:

End point type Secondary

End point timeframe:  
until EoS (60 months of FUP)

End point values	FAS			
Subject group type	Subject analysis set			
Number of subjects analysed	152			
Units: subjects				
survived	125			
deceased	27			

### Statistical analyses

No statistical analyses for this end point

### Secondary: breast-preserving surgery

End point title breast-preserving surgery

End point description:

End point type	Secondary
End point timeframe: after EoT	

<b>End point values</b>	FAS			
Subject group type	Subject analysis set			
Number of subjects analysed	152			
Units: subjects				
yes	107			
no	41			
premature EoT w/o surgery	4			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Treatment-associated toxicity of WHO grade >2

End point title	Treatment-associated toxicity of WHO grade >2
End point description:	

End point type	Secondary
End point timeframe: until the end of (S)AE reporting period	

<b>End point values</b>	FAS			
Subject group type	Subject analysis set			
Number of subjects analysed	152			
Units: subjects				
Yes	110			
No	42			

### Statistical analyses

No statistical analyses for this end point

### Secondary: SAE occurred

End point title	SAE occurred
End point description:	

End point type	Secondary
----------------	-----------

End point timeframe:  
until the end of (S)AE reporting period

<b>End point values</b>	FAS			
Subject group type	Subject analysis set			
Number of subjects analysed	152			
Units: subjects				
yes	28			
no	124			

### Statistical analyses

No statistical analyses for this end point

### Other pre-specified: tox-associated premature EoT

End point title | tox-associated premature EoT

End point description:

End point type | Other pre-specified

End point timeframe:  
during chemotherapy (max. 6 cycles)

<b>End point values</b>	FAS			
Subject group type	Subject analysis set			
Number of subjects analysed	152			
Units: subjects				
Yes	6			
no	146			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first chemotherapy cycle up to 8 weeks after Administration of the last neoadjuvant chemotherapy cycle

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.0
--------------------	------

### Reporting groups

Reporting group title	Safety
-----------------------	--------

Reporting group description:

This set of patients is identical to the FAS.

The number of death refers to the entire period of observation (see sEP overall survival).

Serious adverse events	Safety		
Total subjects affected by serious adverse events			
subjects affected / exposed	28 / 152 (18.42%)		
number of deaths (all causes)	27		
number of deaths resulting from adverse events	2		
Vascular disorders			
Subclavian vein thrombosis			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Venous thrombosis limb			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haematoma			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest pain			

subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Device dislocation			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fatigue			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	5 / 5		
deaths causally related to treatment / all	0 / 0		
Mucosal inflammation			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Multi-organ failure			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Pyrexia			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	2 / 152 (1.32%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	2 / 152 (1.32%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Investigations			
Haemoglobin decreased			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Craniocerebral injury			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardiomyopathy			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Anaemia			
subjects affected / exposed	5 / 152 (3.29%)		
occurrences causally related to treatment / all	6 / 6		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			

subjects affected / exposed	3 / 152 (1.97%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
<b>Granulocytopenia</b>			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Leukopenia</b>			
subjects affected / exposed	11 / 152 (7.24%)		
occurrences causally related to treatment / all	20 / 20		
deaths causally related to treatment / all	0 / 0		
<b>Neutropenia</b>			
subjects affected / exposed	7 / 152 (4.61%)		
occurrences causally related to treatment / all	10 / 10		
deaths causally related to treatment / all	0 / 0		
<b>Pancytopenia</b>			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Thrombocytopenia</b>			
subjects affected / exposed	4 / 152 (2.63%)		
occurrences causally related to treatment / all	4 / 4		
deaths causally related to treatment / all	0 / 0		
<b>Gastrointestinal disorders</b>			
<b>Diarrhoea</b>			
subjects affected / exposed	4 / 152 (2.63%)		
occurrences causally related to treatment / all	4 / 4		
deaths causally related to treatment / all	0 / 0		
<b>Enteritis</b>			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Nausea</b>			

subjects affected / exposed	6 / 152 (3.95%)		
occurrences causally related to treatment / all	6 / 6		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	4 / 152 (2.63%)		
occurrences causally related to treatment / all	4 / 4		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal failure			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Bone pain			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abdominal wall abscess			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abscess			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Infection			
subjects affected / exposed	3 / 152 (1.97%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		

Influenza			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Localised infection			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Mastitis			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	2 / 152 (1.32%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	1 / 1		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hypocalcaemia			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			
subjects affected / exposed	1 / 152 (0.66%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 4 %

<b>Non-serious adverse events</b>	Safety		
Total subjects affected by non-serious adverse events subjects affected / exposed	110 / 152 (72.37%)		
Vascular disorders Hot flush subjects affected / exposed occurrences (all)	6 / 152 (3.95%) 12		
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)  Granulocytopenia subjects affected / exposed occurrences (all)  Leukopenia subjects affected / exposed occurrences (all)  Thrombocytopenia subjects affected / exposed occurrences (all)	7 / 152 (4.61%) 9  40 / 152 (26.32%) 113  64 / 152 (42.11%) 202  8 / 152 (5.26%) 15		
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)  Mucosal inflammation subjects affected / exposed occurrences (all)	11 / 152 (7.24%) 20  7 / 152 (4.61%) 15		
Gastrointestinal disorders Intestinal obstruction subjects affected / exposed occurrences (all)  Nausea subjects affected / exposed occurrences (all)	4 / 152 (2.63%) 9  7 / 152 (4.61%) 9		

Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	35 / 152 (23.03%)		
occurrences (all)	114		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported